A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m(2) (Dralitem(®) vs. Temodal(®) Capsules) in Patients with Primary Tumors of t...

por Muggeri, Alejandro, Vago, Miguel, Pérez, Sebastián, Rubio, Marcelo, González, Cecilia, Magariños, Cristian, Rosenberg, Mónica, Costa, Fernando, Pérez-Lloret, Santiago
Publicado 2017